Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Corvus Pharmaceuticals reported revenue of $0. Net income was -$15.3M, or -$0.53 per diluted share. Operating activities generated -$32.8M of cash, leaving -$33.0M of free cash flow. At fiscal year end, Corvus Pharmaceuticals held $71.1M in total assets against $9.9M in total liabilities, including $4.6M of cash and equivalents.
Open the full interactive Corvus Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Corvus Pharmaceuticals Key Stats
| Share Price | $9.41 |
|---|---|
| Market Cap | $869.2M |
| 52-Week Range | $6.50 – $25.52 |
| Shares Outstanding | 92.4 million (basic, 2026 Q2) |
Corvus Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$43.8M | -$38.6M | -$32.6M | -$23.4M | -$27.5M | -$43.0M |
| Pre-Tax Income | -$6.0M | -$43.2M | -$41.3M | -$27.0M | -$59.1M | -$13.3M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$6.0M | -$43.2M | -$41.3M | -$27.0M | -$62.3M | -$15.3M |
| Diluted EPS | -$0.20 | -$1.03 | -$0.89 | -$0.56 | -$1.02 | -$0.53 |
Corvus Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$10.2M | -$12.3M | -$13.7M | -$18.0M |
| Diluted EPS | -$0.12 | -$0.15 | -$0.15 | -$0.19 |
Corvus Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.5M | $63.5M | $13.2M | $12.6M | $8.7M | $4.6M |
| Current Assets | $45.3M | $71.3M | $43.7M | $28.0M | $54.4M | $58.2M |
| Total Assets | $85.5M | $109.5M | $68.2M | $45.6M | $68.9M | $71.1M |
| Current Liabilities | $12.1M | $9.7M | $10.8M | $6.9M | $35.4M | $9.4M |
| Total Liabilities | $13.4M | $12.3M | $12.1M | $6.9M | $36.3M | $9.9M |
| Shareholders' Equity | $72.1M | $97.2M | $56.1M | $38.7M | $32.6M | $61.2M |
Corvus Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$34.8M | -$36.7M | -$27.0M | -$23.9M | -$25.4M | -$32.8M |
| Cash From Investing | $44.8M | $21.6M | -$23.3M | $15.5M | -$27.5M | -$7.8M |
| Cash From Financing | $1.3M | $62.2M | — | $7.9M | $49.0M | $36.4M |
| Free Cash Flow | -$34.9M | -$36.7M | -$27.3M | -$23.9M | -$25.5M | -$33.0M |
Figures from Corvus Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Corvus Pharmaceuticals financials page for every line item.
Corvus Pharmaceuticals Company Profile
| Ticker | CRVS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001626971 |
Frequently Asked Questions
What was Corvus Pharmaceuticals' revenue in fiscal 2025?
Corvus Pharmaceuticals (CRVS) reported revenue of $0 for fiscal 2025.
What is Corvus Pharmaceuticals' annual revenue history?
Corvus Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Corvus Pharmaceuticals' net income in fiscal 2025?
Corvus Pharmaceuticals reported net income of -$15.3M for fiscal 2025.
What was Corvus Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Corvus Pharmaceuticals' diluted EPS was -$0.53 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Corvus Pharmaceuticals generate in fiscal 2025?
Corvus Pharmaceuticals generated -$33.0M of free cash flow in fiscal 2025.
What was Corvus Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Corvus Pharmaceuticals reported revenue of $0.
How many shares of Corvus Pharmaceuticals are outstanding?
Corvus Pharmaceuticals reported a weighted average of 92.4 million basic shares outstanding in 2026 Q2.
What is Corvus Pharmaceuticals' market cap?
Based on its latest closing price, Corvus Pharmaceuticals (CRVS) has a market capitalization of about $869.2M.
When does Corvus Pharmaceuticals' fiscal year end?
Corvus Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Corvus Pharmaceuticals headquartered?
Corvus Pharmaceuticals lists its business address in South San Francisco, California in its SEC filings.